FAMy Study BMS CA054-010

{ "short_title": "FAMy Study BMS CA054-010", "data_mode": "900", "data_mode_number": "000002295", "official_title": "Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis. ", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": null, "eudract_number": "2021-003650-23", "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Dr. Katja Sockel", "description_laie_de": "Fedratinib in Kombination mit CC-486, einem Hypomethylierungsmittel, bei Patienten mit Myelofibrose in beschleunigter Phase.", "description_laie_en": "Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis.", "description_expert_de": "Fedratinib in Kombination mit CC-486, einem Hypomethylierungsmittel, bei Patienten mit Myelofibrose in beschleunigter Phase.", "description_expert_en": "Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I_II", "main_cat_id": 4, "sub_cat_id": 22 }